PKPunam Kumari

Punam Kumari

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Punam Kumari has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Mechanistic Insights into Houttuynia cordata Thunb. as a Potential Therapeutic Strategy Targeting Metabolic Disorders in Preclinical Models

    by Manashi Karmakar, Binita Chakraborty, Simanta Jyoti Chetia, Nasrin Haque, Punam Kumari, Ameena Ahmed, Pervej Alom Barbhuiya, Pratap Kalita, Kalyani Pathak, Manash Pratim Pathak

  • Open Access

    Essential oils from spices and herbs as a functional ingredient for mitigating metabolic dysfunction-associated steatosis liver disease (MASLD)

    by Manashi Karmakar, Binita Chakraborty, Punam Kumari, Pervej Alom Barbhuiya, Sunandan Baruah, Manash Pratim Sarma, Srijita Chakrabarti, Manash Pratim Pathak


  • Top Cited Papers

    Advanced encapsulation techniques for essential oils: enhancing stability and bioavailability through nanocarriers

    by Ameena Ahmed, Pervej Alom Barbhuiya, Punam Kumari, Srijita Chakrabarti, Manash Pratim Pathak


  • Therapeutic Potential of Citrus Species Against Metabolic Syndrome: Insights from Preclinical and Clinical Studies

    by Punam Kumari, Pervej Alom Barbhuiya, Manash Pratim Pathak

    Metabolic syndrome (MetSyn) is a multifactorial disorder affecting 12.5-31.4% of adults characterized by a cluster of conditions including obesity, type 2 diabetes, hypertension, cardiovascular diseases, and dyslipidemia. Lifestyle and dietary interventions are essential components of its management. With growing interest in natural sources, citrus species are one source that has been traditionally used to treat the symptoms of MetSyn. This review paper aims to provide a comprehensive summary of preclinical and clinical studies to assess the effects of citrus species and their derived phytoconstituents, such as flavonoids, limonoids, and carotenoids, on key metabolic parameters. To evaluate the therapeutic potential of citrus species in the prevention and management of metabolic syndrome based on preclinical studies using essential oils and extracts, clinical studies, and the activity of their bioactive phytoconstituents. Citrus species such as Citrus limon, Citrus medica, Citrus bergamia, Citrus aurantifolia, Citrus aurantium, Citrus grandis, Citrus maxima, Citrus sinensis, Citrus assamensis, Citrus sphaerocarpa, Citrus reticulata, Citrus japonica, and Citrus unshiu have been reported to treat metabolic syndrome. Preclinical studies demonstrate that citrus essential oils and extracts improve insulin sensitivity, reduce body weight and lipid levels, and aid in blood pressure regulation. Prominent bioactive phytoconstituents from citrus species include d-limonene, β-pinene, neral, citronellal, thymol, β-sitosterol, oleic acid, limonene, linalool, citral, α-pinene, coumarin, hexadecenoic acid, hesperidin, neohesperidin, eugenol, geraniol, and p-cymene, have also been reported to demonstrate anti-obesity, antidiabetics, antihypertensive, antidyslipidemic, and cardiovascular protective properties. Clinical trials support these findings, showing significant improvements in metabolic markers in human subjects following citrus-based interventions. Citrus species, due to their rich phytochemical composition, show considerable promise as natural therapeutic agents for mitigating the risks associated with metabolic syndrome. Further well-designed clinical trials are warranted to establish standardized dosages, to concentrate on their mechanisms of action, routes of administration, safe dosage, and potential side effects to ensure their efficacy and safety in treating MetSyn.


  • Natural Oil and Polycystic Ovary Syndrome: A Comprehensive Review ofTherapeutic Benefits

    by Punam Kumari, Pervej Alom Barbhuiya, Ireenia Warjri, Manash Pratim Pathak

    Introduction: Polycystic ovary syndrome (PCOS) is a common endocrine and metabolic disorder affecting 70-75% of women. This condition is frequently linked with large and dysfunctional ovaries, high levels of androgens, and insulin resistance. A variety of conventional treatments, including metformin, oral contraceptives, and anti-androgen agents, have been used to treat PCOS and its complications, but they have been linked to several negative side effects, including hyperkalemia, weight gain, cardiovascular and hepatic toxicity, vitamin B12 and folic acid deficiency. As a result, there is growing interest in natural methods as complementary or alternative approaches to mitigate these side effects. According to several studies, traditionally used Natural oils (NOs) from various sources have been utilized to identify their ameliorating characteristics against PCOS. The paper aims to study pre-clinical investigations and clinical studies of NOs from different sources against PCOS and gives a comprehensive overview of controlling PCOS. Also, it highlights and tabulates the prominent bioactive phytoconstituents from the reported NOs and their mechanism of action. Methods: For this review purpose, the authors have gone through a vast number of scientific literature from different scientific databases like Google Scholar, ScienceDirect, Web of Science, and PubMed. Result: Mentha spicata L., Foeniculum vulgare Mill., Linum usitatissimum L., Nigella sativa L., Bambusa bambos (L.) Voss, Thuja occidentalis L., Syzygium aromaticum L., Pimpinella anisum L., Rosa canina L., Cocos nucifera L., Oenothera biennis L., Corylus avellana L., and fish oil have been reported to have anti-PCOS activity by maintaining body weight, testosterone, LH, FSH levels, and improving ovarian cysts. Discussion: NOs derived from plant and animal sources show promise in treating PCOS by balancing hormone levels, enhancing ovarian morphology, and alleviating metabolic symptoms. However, significant clinical trials and molecular research are required to evaluate their therapeutic potential, identify suitable dosages, investigate their precise mechanisms of action, and ensure long-term safety and efficacy in PCOS management. Conclusion: Further research is needed to understand the molecular mechanisms of NOs responsible for anti-PCOS activity. Studies are needed to concentrate on their mechanisms of action, routes of impact, safe dosage, and potential side effects to ensure their efficacy and safety in treating PCOS.


  • Marine Species, Metabolites and Macromolecules as Potential Therapeutics Against Obesity and Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD): A Comprehensive Review

    by Pervej Alom Barbhuiya, Smitakshi Talukdar, Nur Shaid Mondal, Punam Kumari, Muskaan Ahmed, Manash Pratim Pathak

    Introduction: Many metabolic diseases, such as Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD), are largely caused by obesity, a complicated ailment characterized by excessive fat buildup. By 2030, obesity is expected to have increased in prevalence, affecting over 1 billion people worldwide. MASLD, formerly known as NAFLD, is a broad category of liver illnesses caused by metabolic dysfunction and frequently linked to obesity. Drugs are available for obesity, but long-term use causes serious adverse effects, as reported. Currently, there are no FDA-approved therapies for MASLD. Interest in marine animals and their metabolites for their potential as therapeutics is growing, given the shortcomings of traditional medicines. This review emphasizes different marine species and metabolites, and macromolecules and tabulates all the pre-clinical studies targeting obesity and MASLD. Methodology: For this review, the authors have gone through a vast number of article sources from different scientific databases like PubMed, Google Scholar and ScienceDirect. Results: Algae, fungi, and bacteria found in the ocean are abundant in bioactive chemicals that have anti-obesity and anti-MASLD properties. A variety of studies have reported the anti-obesity and anti-MASLD effects of marine species such as Spirulina platensis, Chlorella vulgaris, Caulerpa okamurae, and bioactive macromolecules like dieckol, fucosterol, fucoxanthin, sodium alginate and paramylon. Conclusion: These marine-derived substances have a variety of pharmacological characteristics, including lipid-modulating, anti-adipogenic, antioxidant, and anti-inflammatory activities. These qualities are crucial for treating the underlying mechanisms that underlie obesity and MASLD. These marine species may be useful as natural supplements or therapeutic agents in the management and treatment of metabolic diseases associated with obesity. Some of these bioactive phytoconstituents have been identified for their potential against obesity and MASLD; however, more investigation is necessary to identify the precise bioactive substances causing these advantageous effects and assess their safety and effectiveness in clinical trials.